| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT05184101 Details | 2024-02-26 Interventional | 2/3 | 0 | Calcium heparin Heparin COVID-19 | COVID-19 hospitalisations limited in Australia, unable to recruit patients due to low numbers
of hospitalisations. - | |||
| NCT05093517 Details | 2024-02-26 Interventional | 1 | - | Volagidemab Diabetes Mellit… Glucose Intoler… Insulin Resista… Glucose Toleran… Insulin Sensiti… Type 2 Diabetes | Temporarily closed to enrollment, pending funding - | |||
| NCT05065411 Details | 2024-02-26 Interventional | 3 | 5 | Everolimus Exemestane Fulvestrant Breast Neoplasm… Metastatic Brea… | Business decision - | |||
| NCT04912063 2021-000514-41 Details | 2024-02-26 Interventional | 1 | 40 | Azacitidine Venetoclax Leukemia Leukemia, Myelo… Leukemia, Myelo… Myelodysplastic… Preleukemia Syndrome Acute Myeloid L… Myelodysplastic… | Strategic considerations - | |||
| NCT03221751 Details | 2024-02-26 Interventional | 4 | 9 | Prazosin Dementia | staffing issues and COVID These results are not generalizable due to the small sample size. | |||
| NCT05679479 Details | 2024-02-23 Interventional | 3 | 108 | Meplazumab COVID-19 | According to the covid-19 epidemic situation in China, there is few sever covid-19 patients. - | |||
| NCT05571267 Details | 2024-02-23 Interventional | 2 | 1 | Aflibercept Bevacizumab Ranibizumab Macular Degener… | Following Sponsor reassessment, OPH2004 enrollment was stopped to initiate a new Zimura wet AMD
trial, OPH2007, for treatment-naïve patients. Thus, only one patient was enrolled into and
completed Study OPH2004. Following the Sponsor's reassessment of the Zimura development program, enrollment was stopped in this trial as the Sponsor determined that they would initiate a new Zimura wet AMD trial, the OPH2007 trial, for treatment-naïve patients. Therefore, a total of two patients were screened, one of whom was a screen failure. Thus, only one patient was enrolled into Study OPH2004. | |||
| NCT05357898 Details | 2024-02-23 Interventional | 1/2 | 20 | Pembrolizumab Neoplasms Adult Solid Tum… | Corporate Decision - | |||
| NCT05345938 Details | 2024-02-23 Interventional | 1/2 | 1 | Mitoxantrone Leukemia Leukemia, Myelo… Leukemia, Myelo… Relapsed or Ref… | Adjust the research strategy. - | |||
| NCT05209529 2022-003594-33 Details | 2024-02-23 Interventional | 2 | 0 | Durvalumab Olaparib Breast Neoplasm… Triple Negative… BRCA1 Mutation BRCA2 Mutation TNBC - Triple-N… | Withdrawn interest from grant provider - | |||
| NCT05116774 2020-004438-39 Details | 2024-02-23 Interventional | 2 | 12 | Eculizumab Ravulizumab Hemoglobinuria Hemoglobinuria,… Paroxysmal Noct… | Sponsor decision - | |||
| NCT04927481 Details | 2024-02-23 Interventional | 2 | 28 | Mitoxantrone Breast Neoplasm… Breast Cancer | The sponsor has adjusted its R&D strategy. - | |||
| NCT04892043 Details | 2024-02-23 Interventional | 1 | 5 | Ipilimumab Nivolumab Neoplasms Adult Solid Tum… | Corporate Decision - | |||
| NCT04489732 Details | 2024-02-23 Interventional | 1 | 6 | Interferon-gamm… Interferons Head and Neck N… Xerostomia Xerostomia Foll… | Unanticipated event - | |||
| NCT03709706 Details | 2024-02-23 Interventional | 1/2 | 34 | Pembrolizumab Carcinoma, Non-… Lung Neoplasms Neoplasms | The study was terminated for reasons pertaining to feasibility - | |||
| NCT02387957 Details | 2024-02-23 Interventional | 2 | 63 | Aflibercept Bevacizumab Ranibizumab Macular Degener… Age-Related Mac… | - - | |||
| NCT02214628 Details | 2024-02-23 Interventional | 2 | 101 | Becaplermin Macular Degener… Age-related Mac… | - - | |||
| NCT01944839 Details | 2024-02-23 Interventional | 3 | 619 | Ranibizumab Macular Degener… Age-Related Mac… | - - | |||
| NCT01940900 Details | 2024-02-23 Interventional | 3 | 627 | Ranibizumab Macular Degener… Age-Related Mac… | - - | |||
| NCT01940887 Details | 2024-02-23 Interventional | 3 | 645 | Aflibercept Bevacizumab Macular Degener… Age-Related Mac… | - - |